Background: Breast cancer is a major health issue responsible for numerous deaths worldwide. Medicinal plants are rich in compounds with potential anticancer properties. Objectives: This study aimed to assess the cytotoxicity of fractions from the Dracontium spruceanum chloroform extract on MDA-MB-231 and MCF-7 breast cancer cell lines. Methods: Eleven fractions were screened for cytotoxic effects on cell viability using the MTT assay. Subsequently, the two most cytotoxic fractions were selected, and the half-maximal inhibitory concentration (IC50) was calculated using two-fold dilution concentrations ranging from 100 to 1.56 µg/mL. Results: Fractions F43 and F50 showed the highest cytotoxicity at 100 µg/mL. The IC50 of F43 was 270.8 ± 18.07 µg/mL and 133.0 ± 17.99 µg/mL for MDA-MB-231, and 252.2 ± 21.94 µg/mL and 144.3 ± 23.14 µg/mL for MCF-7 cells at 24 and 48 hours, respectively. For F50, IC50 values were 107.2 ± 2.97 µg/mL and 126.1 ± 14.77 µg/mL for MDA-MB-231, and 236.4 ± 58.7 µg/mL and 104.5 ± 10.54 µg/mL for MCF-7 at corresponding times. Conclusions: Dracontium spruceanum fractions demonstrated moderate cytotoxicity on MDA-MB-231 and MCF-7 breast cancer cell lines, indicating their anticancer potential. Further research is required to identify the metabolites responsible for this activity and to elucidate the molecular mechanisms involved.
No takes yet. Share an insight, caveat, or question.
Rodriguez-Huamani et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: